Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029780 · ClinicalTrials.gov registry record · Phase 2
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT03029780 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 104 participants.
The verdict
NCT03029780, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and efficacy of different administration regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.
Interventions
- BIOLOGICAL Opdivo
- BIOLOGICAL Yervoy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2017-02-16 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03029780
The ClinicalTrials.gov registry entry for NCT03029780 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Opdivo is the first listed.
NCT03029780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03029780 about?
NCT03029780 is a clinical study titled "An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma". The purpose of this study is to evaluate safety and efficacy of different administration regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.
What is the current status of trial NCT03029780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2017-02-16. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT03029780?
The interventions under investigation include: Opdivo (BIOLOGICAL), Yervoy (BIOLOGICAL).
Who is sponsoring clinical trial NCT03029780?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.